Improving existing tools for Mycobacterium xenopi treatment: Assessment of drug combinations and characterization of mouse models of infection and chemotherapy

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 3, 2013, Pages 659-665

  Andréjak, Claire ^a,b,c   Almeida, Deepak V ^a   Tyagi, Sandeep ^a   Converse, Paul J ^a   Ammerman, Nicole C ^a   Grosset, Jacques H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSERM   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Clarithromycin; Drug susceptibility testing; Ethambutol; Nude mouse

Indexed keywords

AMIKACIN; CLARITHROMYCIN; ETHAMBUTOL; ISONIAZID; LINEZOLID; MOXIFLOXACIN; RIFAMPICIN; RIFAPENTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; DRUG ACTIVITY; EX VIVO STUDY; FEMALE; IN VITRO STUDY; LUNG INFECTION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM XENOPEI; NONHUMAN;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; MYCOBACTERIUM XENOPI; TREATMENT OUTCOME;

EID: 84873602823     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks421     Document Type: Article

References (32)

1. Andréjak C, Lescure FX, Pukenyte E et al. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in North-East France. Thorax 2009; 64: 291-6.
2. Andréjak C, Thomsen VØ, Johansen IS et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010; 181: 514-21.
3. Smith MJ, Citron KM. Clinical review of pulmonary disease caused by Mycobacterium xenopi. Thorax 1983; 38: 373-7.
4. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
5. Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001; 56: 167-72.
6. Ruf B, Schürmann D, Mauch H et al. Effectiveness of the macrolide clarithromycin in the treatment of Mycobacterium avium complex infection in HIV-infected patients. Infection 1992; 20: 267-72.
7. Grosset J, Ji B. Prevention of the selection of clarithromycin-resistant Mycobacterium avium-intracellulare complex. Drugs1997;54 Suppl 2:23-7.
8. Wright J. Current strategies for the prevention and treatment of disseminated Mycobacterium avium complex infection in patients with AIDS. Pharmacotherapy 1998; 18: 738-47.
9. Rapp RP, McCraney SA, Goodman NL et al. New macrolide antibiotics: usefulness in infections caused by mycobacteria other than Mycobacterium tuberculosis. Ann Pharmacother 1994; 28: 1255-63.
10. Bakker-Woudenberg IA, van Vianen W, van Soolingen D et al. Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination. Antimicrob Agents Chemother 2005; 49: 2387-98.
11. Banks J, Jenkins PA. Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria. Thorax 1987; 42: 838-42.
12. Heifets LB. Synergistic effect of rifampin, streptomycin, ethionamide, and ethambutol on Mycobacterium intracellulare. Am Rev Respir Dis 1982; 125: 43-8.
13. Lounis N, Truffot-Pernot C, Bentoucha A et al. Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. Antimicrob Agents Chemother 2001; 45: 3229-30.
14. Klemens SP, Cynamon MH. Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice. Antimicrob Agents Chemother 1994; 38: 1455-9.
15. Gangadharam PR, Edwards CK 3rd, Murthy PS et al. An acute infection model for Mycobacterium intracellulare disease using beige mice: preliminary results. Am Rev Respir Dis 1983; 127: 648-9.
16. Collins FM, Stokes RW. Mycobacterium avium-complex infections in normal and immunodeficient mice. Tubercle 1987; 68: 127-36.
17. Torreles JB, Ellos D, Osborne T et al. Characterization of virulence, colony, morphotype and the glycopeptidolipid of Mycobacterium avium strain 104. Tuberculosis 2002; 82: 293-300.
18. Lorian V. Antibiotics in Laboratory Medicine. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
19. Truffot-Pernot C, Ji B, Grosset J. Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. Antimicrob Agents Chemother 1991; 35: 1677-8.
20. Gradelski E, Kolek B, Bonner DP et al. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents. Int J Antimicrob Agents 2001; 17: 103-7.
21. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
22. Niemi M, Backman JT, Fromm MF et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819-50.
23. Chu S, Wilson DS, Deaton RL et al. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 1993; 33: 719-26.
24. Garnham JC, Taylor T, Turner P et al. Serum concentrations and bioavailability of rifampicin and isoniazid in combination. Br J Clin Pharmacol 1976; 3: 897-902.
25. Keung A, Eller MG, McKenzie KA et al. Single and multiple dose pharmacokinetics of rifapentine in man: part II. Int J Tuberc Lung Dis 1999; 3: 437-44.
26. Kirby WM, Clarke JT, Libke RD et al. Clinical pharmacology of amikacin and kanamycin. J Infect Dis 1976; 134 Suppl: S312-5.
27. Lee CS, Gambertoglio JG, Brater DC et al. Kinetics of oral ethambutol in the normal subject. Clin Pharmacol Ther 1977; 22: 615-21.
28. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42: 1129-40.
29. Stass H, Dalhoff A, Kubitza D et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42: 2060-5.
30. Takayama K, Kilburn JO. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 1989; 33: 1493-9.
31. Baugnée PE, Pouthier F, Delaunois L. Pulmonary mycobacteriosis due to Mycobacterium xenopi "in-vitro" sensitivity to classical antitubercular agents and clinical development. Acta Clin Belg 1996; 51: 19-27.
32. Jenkins PA, Campbell IA, Banks J et al. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008; 63: 627-34.